Skip to main content
Top
Published in: Clinical Rheumatology 9/2017

Open Access 01-09-2017 | Original Article

Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping

Authors: Daniel Stekhoven, Almut Scherer, Michael J. Nissen, Véronique Grobéty, Nikhil Yawalkar, Peter M. Villiger, Burkhard Möller, on behalf of the Swiss Clinical Quality Management for Rheumatic Diseases

Published in: Clinical Rheumatology | Issue 9/2017

Login to get access

Abstract

Current ClASsification criteria for Psoriatic ARthritis classification criteria for psoriatic arthritis (PsA) provide a preliminary definition of inflammatory articular disease. This study aimed to further characterize PsA peripheral arthritis using purely data-driven approaches for the affected joint distribution pattern. PsA patients from the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database were clustered according to similarities in 66 swollen and in 68 tender joints. Clusters were compared in terms of other disease characteristics and studied for coincidence with traditional PsA subtypes, stability over time and treatment response upon first tumour necrosis factor alpha (TNF-α) therapy. Clustering of 957 patients resulted in an oligoarticular, a polyarticular hand dominated, a polyarticular foot dominated and a fourth cluster which was characterized by polyarticular involvement of the hands and feet. Of the traditional PsA subtypes, only a non-PsA-specific oligoarticular joint involvement pattern was retrieved by clustering. When comparing clusters in other disease manifestations, only minor and clinically probably irrelevant differences occurred. Over time, clusters were more robust than traditional PsA subtypes. Patients in different joint clusters had similar response rates upon first anti-TNF-α therapy, and minimal disease activity was achieved in 56% of 285 patients, irrespective of cluster membership. Hypothesis-free approaches to group PsA patients yield clusters with improved consistency, but without clinically important differences. Taken together, the current peripheral arthritis definition by GRAPPA without further specification into subtypes is strongly supported by the data.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerback C, Gudjonsson JE, Koks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nothen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT (2015) Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet 97(6):816–836. doi:10.1016/j.ajhg.2015.10.019 CrossRefPubMedPubMedCentral Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerback C, Gudjonsson JE, Koks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nothen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT (2015) Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet 97(6):816–836. doi:10.​1016/​j.​ajhg.​2015.​10.​019 CrossRefPubMedPubMedCentral
3.
go back to reference Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O (2016) Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 75(1):155–162. doi:10.1136/annrheumdis-2014-205461 CrossRefPubMed Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O (2016) Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 75(1):155–162. doi:10.​1136/​annrheumdis-2014-205461 CrossRefPubMed
7.
go back to reference Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ (1994) Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 33(9):834–839CrossRefPubMed Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ (1994) Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 33(9):834–839CrossRefPubMed
11.
go back to reference Gladman D (1993) Psoriatic arthritis. In: Maddison PJID, Woo P, Glass DN (eds) Oxford textbook of rheumatology, vol 2. Oxford Medical Publications, Oxford, pp 691–698 Gladman D (1993) Psoriatic arthritis. In: Maddison PJID, Woo P, Glass DN (eds) Oxford textbook of rheumatology, vol 2. Oxford Medical Publications, Oxford, pp 691–698
12.
go back to reference Hui MDM, da Silva J (2012) Diagnostic strategies. In: Textbook on rheumatic diseases, vol 1, 1st edn. BMJ Group, London Hui MDM, da Silva J (2012) Diagnostic strategies. In: Textbook on rheumatic diseases, vol 1, 1st edn. BMJ Group, London
16.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. doi:10.1002/art.21972 CrossRefPubMed Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. doi:10.​1002/​art.​21972 CrossRefPubMed
17.
go back to reference Mainland D (1965) Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 8:302–335CrossRef Mainland D (1965) Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 8:302–335CrossRef
18.
go back to reference Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1):44–48 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1):44–48
19.
go back to reference Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9(5):789–793PubMed Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9(5):789–793PubMed
20.
go back to reference Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216CrossRefPubMed Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216CrossRefPubMed
22.
go back to reference Mease PJ, Heckaman M, Kary S, Kupper H (2013) Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 40(5):647–652. doi:10.3899/jrheum.120970 CrossRefPubMed Mease PJ, Heckaman M, Kary S, Kupper H (2013) Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 40(5):647–652. doi:10.​3899/​jrheum.​120970 CrossRefPubMed
23.
go back to reference Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J (2007) Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34(5):1167–1170PubMed Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J (2007) Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34(5):1167–1170PubMed
24.
go back to reference Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 57(1):289–300 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 57(1):289–300
25.
go back to reference Coates LC, FitzGerald O, Gladman DD, McHugh N, Mease P, Strand V, Helliwell PS (2013) Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum 65(6):1504–1509. doi:10.1002/art.37939 CrossRefPubMed Coates LC, FitzGerald O, Gladman DD, McHugh N, Mease P, Strand V, Helliwell PS (2013) Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum 65(6):1504–1509. doi:10.​1002/​art.​37939 CrossRefPubMed
26.
go back to reference Scott DL, Choy EH, Greeves A, Isenberg D, Kassinor D, Rankin E, Smith EC (1996) Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 15(6):579–582CrossRefPubMed Scott DL, Choy EH, Greeves A, Isenberg D, Kassinor D, Rankin E, Smith EC (1996) Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 15(6):579–582CrossRefPubMed
27.
go back to reference Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, Luime JJ, Elkayam O, Neerinckx B, Urbancek S, de Vlam K, Ritchlin CT, Group GEW (2014) Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 41(11):2290–2294. doi:10.3899/jrheum.140878 CrossRefPubMed Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, Luime JJ, Elkayam O, Neerinckx B, Urbancek S, de Vlam K, Ritchlin CT, Group GEW (2014) Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 41(11):2290–2294. doi:10.​3899/​jrheum.​140878 CrossRefPubMed
30.
go back to reference Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O’Keeffe AG, Maddison PJ, Scott DL (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51(8):1368–1377. doi:10.1093/rheumatology/kes001 CrossRef Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O’Keeffe AG, Maddison PJ, Scott DL (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51(8):1368–1377. doi:10.​1093/​rheumatology/​kes001 CrossRef
31.
go back to reference Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2015) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-208337 Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2015) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2015-208337
32.
go back to reference Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D (2012) Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 71(6):891–898. doi:10.1136/ard.2011.149849 CrossRefPubMed Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D (2012) Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 71(6):891–898. doi:10.​1136/​ard.​2011.​149849 CrossRefPubMed
33.
go back to reference Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, Mulleman D, Lukas C, Wendling D, Lafforgue P, Loeuille D, Foltz V, Richette P, French section of o (2015) Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 74(9):1697–1705. doi:10.1136/annrheumdis-2014-205348 CrossRefPubMed Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, Mulleman D, Lukas C, Wendling D, Lafforgue P, Loeuille D, Foltz V, Richette P, French section of o (2015) Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 74(9):1697–1705. doi:10.​1136/​annrheumdis-2014-205348 CrossRefPubMed
34.
go back to reference Thavaneswaran A, Chandran V, Gladman D (2013) Cluster analysis of psoriatic arthritis patients at follow-up [abstract]. Arthritis Rheum 65(Suppl 10):336 Thavaneswaran A, Chandran V, Gladman D (2013) Cluster analysis of psoriatic arthritis patients at follow-up [abstract]. Arthritis Rheum 65(Suppl 10):336
Metadata
Title
Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping
Authors
Daniel Stekhoven
Almut Scherer
Michael J. Nissen
Véronique Grobéty
Nikhil Yawalkar
Peter M. Villiger
Burkhard Möller
on behalf of the Swiss Clinical Quality Management for Rheumatic Diseases
Publication date
01-09-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3637-2

Other articles of this Issue 9/2017

Clinical Rheumatology 9/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.